Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Physiomics
With
Portsmouth Hospitals NHS Trust
National Institute for Health Research, United Kingdom
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with metastatic prostate cancer (hormone sensitive or castrate resistant) and histologically confirmed
Metastatic at disease onset or relapsed disease
A treatment decision has been made to start a course of docetaxel as part of their standard of care treatment in accordance with the drug's label and the treating clinician's judgement
Patient has not received a previous cycle of docetaxel within 8 weeks of the date of enrolment
Life expectancy \> 12 weeks
Participant is willing and able to give informed consent for participation in the study
You may not be if
\- Patients with autoimmune disease receiving active treatments Participant is unable to give informed consent
Clareo Health | Personalizing Docetaxel Dosing in Advanced Prostate Cancer
